Anteris Technologies Global (AVR) Competitors $9.62 +0.62 (+6.89%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$9.65 +0.03 (+0.35%) As of 05/22/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVR vs. SLNO, TMDX, LMAT, AXGN, and NVCRShould you buy Anteris Technologies Global stock or one of its competitors? MarketBeat compares Anteris Technologies Global with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anteris Technologies Global include Soleno Therapeutics (SLNO), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), AxoGen (AXGN), and NovoCure (NVCR). These companies are all part of the "medical equipment" industry. AVR vs. SLNOAVR vs. TMDXAVR vs. LMATAVR vs. AXGNAVR vs. NVCRHow does Anteris Technologies Global compare to Soleno Therapeutics?Soleno Therapeutics (NASDAQ:SLNO) and Anteris Technologies Global (NASDAQ:AVR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Do analysts recommend SLNO or AVR? Soleno Therapeutics currently has a consensus price target of $76.67, indicating a potential upside of 44.63%. Anteris Technologies Global has a consensus price target of $16.00, indicating a potential upside of 66.32%. Given Anteris Technologies Global's stronger consensus rating and higher possible upside, analysts clearly believe Anteris Technologies Global is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 2 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.08Anteris Technologies Global 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has higher earnings & valuation, SLNO or AVR? Soleno Therapeutics has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno Therapeutics$285.01M9.69$20.89M$1.7729.95Anteris Technologies Global$1.91M490.27-$94.14M-$2.23N/A Does the media prefer SLNO or AVR? In the previous week, Anteris Technologies Global had 1 more articles in the media than Soleno Therapeutics. MarketBeat recorded 4 mentions for Anteris Technologies Global and 3 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 0.00 beat Anteris Technologies Global's score of -0.27 indicating that Soleno Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anteris Technologies Global 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in SLNO or AVR? 97.4% of Soleno Therapeutics shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, SLNO or AVR? Soleno Therapeutics has a beta of -2.22, suggesting that its share price is 322% less volatile than the broader market. Comparatively, Anteris Technologies Global has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Is SLNO or AVR more profitable? Soleno Therapeutics has a net margin of 33.70% compared to Anteris Technologies Global's net margin of -5,148.78%. Soleno Therapeutics' return on equity of 22.85% beat Anteris Technologies Global's return on equity.Company Net Margins Return on Equity Return on Assets Soleno Therapeutics33.70% 22.85% 18.25% Anteris Technologies Global -5,148.78%-124.76%-101.21% SummarySoleno Therapeutics beats Anteris Technologies Global on 10 of the 16 factors compared between the two stocks.How does Anteris Technologies Global compare to TransMedics Group?TransMedics Group (NASDAQ:TMDX) and Anteris Technologies Global (NASDAQ:AVR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings. Is TMDX or AVR more profitable? TransMedics Group has a net margin of 27.04% compared to Anteris Technologies Global's net margin of -5,148.78%. TransMedics Group's return on equity of 22.38% beat Anteris Technologies Global's return on equity.Company Net Margins Return on Equity Return on Assets TransMedics Group27.04% 22.38% 8.46% Anteris Technologies Global -5,148.78%-124.76%-101.21% Do analysts rate TMDX or AVR? TransMedics Group presently has a consensus target price of $135.00, suggesting a potential upside of 95.85%. Anteris Technologies Global has a consensus target price of $16.00, suggesting a potential upside of 66.32%. Given TransMedics Group's higher possible upside, equities analysts clearly believe TransMedics Group is more favorable than Anteris Technologies Global.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransMedics Group 0 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50Anteris Technologies Global 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media prefer TMDX or AVR? In the previous week, TransMedics Group had 2 more articles in the media than Anteris Technologies Global. MarketBeat recorded 6 mentions for TransMedics Group and 4 mentions for Anteris Technologies Global. TransMedics Group's average media sentiment score of 0.19 beat Anteris Technologies Global's score of -0.27 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Anteris Technologies Global 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in TMDX or AVR? 99.7% of TransMedics Group shares are held by institutional investors. 6.9% of TransMedics Group shares are held by company insiders. Comparatively, 4.5% of Anteris Technologies Global shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, TMDX or AVR? TransMedics Group has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market. Comparatively, Anteris Technologies Global has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Which has stronger valuation and earnings, TMDX or AVR? TransMedics Group has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTransMedics Group$605.49M3.93$190.29M$4.4015.67Anteris Technologies Global$1.91M490.27-$94.14M-$2.23N/A SummaryTransMedics Group beats Anteris Technologies Global on 14 of the 16 factors compared between the two stocks.How does Anteris Technologies Global compare to LeMaitre Vascular?Anteris Technologies Global (NASDAQ:AVR) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Do institutionals and insiders believe in AVR or LMAT? 84.6% of LeMaitre Vascular shares are held by institutional investors. 4.5% of Anteris Technologies Global shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor AVR or LMAT? In the previous week, LeMaitre Vascular had 3 more articles in the media than Anteris Technologies Global. MarketBeat recorded 7 mentions for LeMaitre Vascular and 4 mentions for Anteris Technologies Global. LeMaitre Vascular's average media sentiment score of 0.63 beat Anteris Technologies Global's score of -0.27 indicating that LeMaitre Vascular is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anteris Technologies Global 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral LeMaitre Vascular 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Is AVR or LMAT more profitable? LeMaitre Vascular has a net margin of 24.35% compared to Anteris Technologies Global's net margin of -5,148.78%. LeMaitre Vascular's return on equity of 15.36% beat Anteris Technologies Global's return on equity.Company Net Margins Return on Equity Return on Assets Anteris Technologies Global-5,148.78% -124.76% -101.21% LeMaitre Vascular 24.35%15.36%9.78% Which has higher valuation & earnings, AVR or LMAT? LeMaitre Vascular has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnteris Technologies Global$1.91M490.27-$94.14M-$2.23N/ALeMaitre Vascular$249.60M8.95$57.73M$2.7136.07 Do analysts prefer AVR or LMAT? Anteris Technologies Global presently has a consensus price target of $16.00, indicating a potential upside of 66.32%. LeMaitre Vascular has a consensus price target of $112.60, indicating a potential upside of 15.19%. Given Anteris Technologies Global's higher probable upside, research analysts plainly believe Anteris Technologies Global is more favorable than LeMaitre Vascular.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anteris Technologies Global 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60LeMaitre Vascular 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Which has more risk & volatility, AVR or LMAT? Anteris Technologies Global has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. SummaryLeMaitre Vascular beats Anteris Technologies Global on 13 of the 16 factors compared between the two stocks.How does Anteris Technologies Global compare to AxoGen?AxoGen (NASDAQ:AXGN) and Anteris Technologies Global (NASDAQ:AVR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership. Do institutionals & insiders hold more shares of AXGN or AVR? 80.3% of AxoGen shares are owned by institutional investors. 2.4% of AxoGen shares are owned by company insiders. Comparatively, 4.5% of Anteris Technologies Global shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is AXGN or AVR more profitable? AxoGen has a net margin of -13.21% compared to Anteris Technologies Global's net margin of -5,148.78%. AxoGen's return on equity of -9.63% beat Anteris Technologies Global's return on equity.Company Net Margins Return on Equity Return on Assets AxoGen-13.21% -9.63% -6.26% Anteris Technologies Global -5,148.78%-124.76%-101.21% Which has more risk and volatility, AXGN or AVR? AxoGen has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market. Comparatively, Anteris Technologies Global has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Do analysts prefer AXGN or AVR? AxoGen currently has a consensus price target of $46.50, indicating a potential upside of 13.69%. Anteris Technologies Global has a consensus price target of $16.00, indicating a potential upside of 66.32%. Given Anteris Technologies Global's higher probable upside, analysts clearly believe Anteris Technologies Global is more favorable than AxoGen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AxoGen 2 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.64Anteris Technologies Global 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media prefer AXGN or AVR? In the previous week, AxoGen had 2 more articles in the media than Anteris Technologies Global. MarketBeat recorded 6 mentions for AxoGen and 4 mentions for Anteris Technologies Global. AxoGen's average media sentiment score of 0.95 beat Anteris Technologies Global's score of -0.27 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anteris Technologies Global 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, AXGN or AVR? AxoGen has higher revenue and earnings than Anteris Technologies Global. AxoGen is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxoGen$225.21M9.66-$15.70M-$0.64N/AAnteris Technologies Global$1.91M490.27-$94.14M-$2.23N/A SummaryAxoGen beats Anteris Technologies Global on 11 of the 16 factors compared between the two stocks.How does Anteris Technologies Global compare to NovoCure?Anteris Technologies Global (NASDAQ:AVR) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Is AVR or NVCR more profitable? NovoCure has a net margin of -25.66% compared to Anteris Technologies Global's net margin of -5,148.78%. NovoCure's return on equity of -50.82% beat Anteris Technologies Global's return on equity.Company Net Margins Return on Equity Return on Assets Anteris Technologies Global-5,148.78% -124.76% -101.21% NovoCure -25.66%-50.82%-16.48% Do analysts recommend AVR or NVCR? Anteris Technologies Global presently has a consensus price target of $16.00, indicating a potential upside of 66.32%. NovoCure has a consensus price target of $27.29, indicating a potential upside of 51.92%. Given Anteris Technologies Global's stronger consensus rating and higher possible upside, equities analysts plainly believe Anteris Technologies Global is more favorable than NovoCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anteris Technologies Global 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60NovoCure 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Do insiders and institutionals believe in AVR or NVCR? 84.6% of NovoCure shares are held by institutional investors. 4.5% of Anteris Technologies Global shares are held by insiders. Comparatively, 5.5% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings and valuation, AVR or NVCR? Anteris Technologies Global has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnteris Technologies Global$1.91M490.27-$94.14M-$2.23N/ANovoCure$655.35M3.17-$136.23M-$1.53N/A Does the media favor AVR or NVCR? In the previous week, Anteris Technologies Global had 1 more articles in the media than NovoCure. MarketBeat recorded 4 mentions for Anteris Technologies Global and 3 mentions for NovoCure. NovoCure's average media sentiment score of 0.09 beat Anteris Technologies Global's score of -0.27 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anteris Technologies Global 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral NovoCure 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, AVR or NVCR? Anteris Technologies Global has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market. Comparatively, NovoCure has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. SummaryNovoCure beats Anteris Technologies Global on 8 of the 15 factors compared between the two stocks. Get Anteris Technologies Global News Delivered to You Automatically Sign up to receive the latest news and ratings for AVR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVR vs. The Competition ExportMetricAnteris Technologies GlobalMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$936.43M$7.11B$6.44B$12.34BDividend YieldN/A1.68%2.76%5.28%P/E Ratio-4.3147.4521.2625.66Price / Sales490.2773.72552.9986.26Price / CashN/A24.9143.6856.73Price / Book3.366.5310.367.14Net Income-$94.14M$158.81M$3.56B$335.80M7 Day Performance32.87%4.60%5.12%3.02%1 Month Performance72.40%0.74%3.54%2.48%1 Year Performance164.29%3.17%34.14%35.08% Anteris Technologies Global Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVRAnteris Technologies Global3.0788 of 5 stars$9.62+6.9%$16.00+66.3%+164.3%$936.43M$1.91MN/A138High Trading VolumeSLNOSoleno Therapeutics3.4233 of 5 stars$53.01+0.0%$76.67+44.6%N/A$2.76B$190.40M29.9530Analyst ForecastTMDXTransMedics Group4.1486 of 5 stars$68.34+8.1%$135.00+97.5%-44.5%$2.36B$605.49M15.53210LMATLeMaitre Vascular4.768 of 5 stars$100.83+3.6%$112.60+11.7%+20.1%$2.30B$249.60M37.21490Analyst UpgradeHigh Trading VolumeAXGNAxoGen3.4321 of 5 stars$41.95+2.3%$46.50+10.8%+269.5%$2.23B$225.21MN/A450Analyst Upgrade Related Companies and Tools Related Companies SLNO Alternatives TMDX Alternatives LMAT Alternatives AXGN Alternatives NVCR Alternatives ESTA Alternatives PLSE Alternatives PRCT Alternatives ENOV Alternatives EYE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVR) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anteris Technologies Global Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anteris Technologies Global With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
